查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678533

全球癲癇治療市場：市場規模、市場佔有率、趨勢分析（按治療方法、分銷管道和地區）、按細分市場預測（2025-2030 年）

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

癲癇藥物市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球癲癇藥物市場規模預計到 2030 年將達到 154.7 億美元，2025 年至 2030 年的複合年成長率為 5.7%。政府增加對治療癲癇發作的新有效藥物的開發資金是推動癲癇藥物市場成長的重要因素。美國癲癇協會 (AES) 與美國神經病學學會、癲癇基金會和格拉斯基金會等其他組織合作，資助研究和開發活動，並透過各種計畫為醫生提供一系列治療意識培訓。

此外，癲癇基金會、美國癲癇協會、中佛羅裡達癲癇協會、治愈癲癇協會和安妮塔考夫曼基金會等組織實施的各種宣傳計劃正在進一步加快診斷和治療率。預計這將在預測期內推動市場成長。

癲癇藥物市場：概述

  • 第二代抗癲癇藥物預計將成為第二快成長速度的領域。此部分包括拉莫三嗪 (Lamictal)、左乙拉西坦 (Keppra)、布瓦萊克坦 (Briviact)、吡崙帕奈 (Fycompa) 等。
  • 第三代抗癲癇藥物領域在 2024 年佔據最大的銷售佔有率，約 39.7%。該領域成長的主要驅動力包括推出作用機制改進、副作用更少的高效藥物，以及即將推出的新藥管線。
  • 2024 年北美將佔據最大的銷售佔有率，約 38.7%。癲癇的高盛行率和受該疾病影響的人數眾多是該地區癲癇藥物市場的主要推動要素。
  • 預計預測期內亞太地區的癲癇藥物市場將實現顯著的複合年成長率。這是因為該地區人口眾多且多樣化，癲癇盛行率迅速上升，以及醫療保健基礎設施不斷改善。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第3章 癲癇藥物市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 癲癇藥物市場：依治療方法進行的商業分析

  • 治療方法的市場佔有率（2024 年和 2030 年）
  • 治療方法儀表板
  • 市場規模預測及治療方法趨勢分析（2018-2030）
  • 第一代抗癲癇藥物
  • 第二代抗癲癇藥物
  • 第三代抗癲癇藥物

第 5 章 癲癇藥物市場：按分銷管道進行的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2030 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測及趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 其他

第6章 癲癇藥物市場：按地區估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • UCB SA
    • Sanofi
    • Pfizer, Inc.
    • Otsuka America Pharmaceutical, Inc.
    • Eisai Co., Ltd.
    • Abbott Laboratories, Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Sunovion Pharmaceuticals, Inc.
    • Jazz Pharmaceuticals plc
    • Neurelis, Inc.
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epilepsy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epilepsy Drugs Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
  • 4.4. First Generation Anti-epileptics
    • 4.4.1. First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.5. Second Generation Anti-epileptics
    • 4.5.1. Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.6. Third Generation Anti-epileptics
    • 4.6.1. Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epilepsy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.K.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB S.A.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Sanofi
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Pfizer, Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Otsuka America Pharmaceutical, Inc.
      • 7.5.4.1. Participant's overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Eisai Co., Ltd.
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Abbott Laboratories, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. GlaxoSmithKline plc
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Sunovion Pharmaceuticals, Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Jazz Pharmaceuticals plc
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Neurelis, Inc.
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Epilepsy Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 North America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.K. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 U.K. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 France Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 France Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Italy Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Spain Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Denmark Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Denmark Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Norway Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Norway Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 China Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 China Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 India Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 South Korea Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Australia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Australia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 UAE Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epilepsy Drugs Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot

Fig. 9 Treatment and Distribution Channel Outlook (USD Million)

  • Fig. 10 Competitive Landscape
  • Fig. 11 Epilepsy Drugs Market Dynamics
  • Fig. 12 Epilepsy Drugs Market: Porter's Five Forces Analysis
  • Fig. 13 Epilepsy Drugs Market: PESTLE Analysis
  • Fig. 14 Epilepsy Drugs Market: Treatment Segment Dashboard
  • Fig. 15 Epilepsy Drugs Market: Treatment Market Share Analysis, 2024 & 2030
  • Fig. 16 First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 17 Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 18 Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 19 Epilepsy Drugs Market: Distribution Channel Segment Dashboard
  • Fig. 20 Epilepsy Drugs Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 21 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 22 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 23 Others Market, 2018 - 2030 (USD Million)
  • Fig. 24 Epilepsy Drugs Market Revenue, By Region
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 North America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Country Dynamics
  • Fig. 29 U.S. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Country Dynamics
  • Fig. 31 Canada Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Country Dynamics
  • Fig. 33 Mexico Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 U.K. Country Dynamics
  • Fig. 36 U.K. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Country Dynamics
  • Fig. 38 Germany Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Country Dynamics
  • Fig. 40 France Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Country Dynamics
  • Fig. 42 Italy Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Country Dynamics
  • Fig. 44 Spain Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark Country Dynamics
  • Fig. 46 Denmark Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway Country Dynamics
  • Fig. 48 Norway Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Country Dynamics
  • Fig. 50 Sweden Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan Country Dynamics
  • Fig. 53 Japan Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 China Country Dynamics
  • Fig. 55 China Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 India Country Dynamics
  • Fig. 57 India Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea Country Dynamics
  • Fig. 59 South Korea Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia Country Dynamics
  • Fig. 61 Australia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand Country Dynamics
  • Fig. 63 Thailand Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil Country Dynamics
  • Fig. 66 Brazil Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina Country Dynamics
  • Fig. 68 Argentina Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East & Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa Country Dynamics
  • Fig. 71 South Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia Country Dynamics
  • Fig. 73 Saudi Arabia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE Country Dynamics
  • Fig. 75 UAE Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key Country Dynamicss
  • Fig. 77 Kuwait Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 78 Company Categorization
  • Fig. 79 Company Market Position Analysis
  • Fig. 80 Strategic Framework